Anal Cancer Market Research Report - Forecast till 2027

Anal Cancer Market Research Report: Information by Cancer Type (Carcinoma in Situ, Squamous Cell Carcinoma, Adenocarcinoma, Basal Cell Carcinoma, Melanoma and others), Treatment Type (Chemotherapy, Surgery, Radiation Therapy and Immunotherapy), End User (Hospitals & Clinics, Research & Academic Institutes and others) - Forecast till 2027

ID: MRFR/MED/1001-HCR | February 2021 | Region: Global | 130 pages

Anal Cancer Market Scenario


Anal Cancer Market is expected to witness significant growth over the forecast period. The market was valued at approximately USD 673.92 million in 2018 and is projected to register a 6.46% CAGR over the forecast period.


Anal cancer is a rare type of malignancy that starts in the anus, which is the opening at the end of the rectum.


Factors such as the rising prevalence of anal cancer and the growing number of sexually transmitted diseases are expected to drive market growth. According to an article published by the American Cancer Society, an estimated 8,300 new cases of anal cancer will be diagnosed in 2019. Moreover, increasing research and development expenditure in the field of oncology is also expected to boost market growth.


However, the side effects of the treatment and lack of awareness are expected to hamper the market growth. 


Segmentation


The anal cancer market has been segmented into cancer type, treatment type, end user, and region.


Based on cancer type, the anal cancer market has been segmented into carcinoma in situ, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, and others.


The anal cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and immunotherapy.


The anal cancer market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The anal cancer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European anal cancer market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 


The anal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.


The Middle East & Africa anal cancer market is segmented into the Middle East and Africa.


Key Players


Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson Services, Inc. (US) and Hospira, Inc. (US) are some of the key players operating in the anal cancer market.


Regional Market Summary


Global Anal Cancer Market Share (%), by Region, 2018


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to dominate the anal cancer market owing to the rising prevalence of anal cancer. According to the American Cancer Society, by 2019, approximately 1,280 people are expected to die from anal cancer.


Europe is expected to hold the second-largest share of the anal cancer market owing to the rising prevalence of anal cancer and presence of major market players such as F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, and Sanofi. According to Cancer Research UK, 1,438 new cases of anal cancer were found in between 2014–2016 in the UK.


Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing awareness regarding cancer and rising prevalence of sexually transmitted diseases.


The anal cancer market in the Middle East & Africa is expected to steadily grow during the forecast period owing to the high incidence rate of anal cancer.


Anal Cancer Market, by Cancer Type



  • Carcinoma in Situ

  • Squamous Cell Carcinoma

  • Adenocarcinoma

  • Basal Cell Carcinoma

  • Melanoma

  • Others


Anal Cancer Market, by End User



  • Hospitals and Clinics

  • Research and Academic Institutes

  • Others


Anal Cancer Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Biotechnology companies

  • Research institutes

  • Medical device companies

  • Pharmaceutical companies

  • Hospitals and clinics

  • Ambulatory surgical centers

  • Academic institutes

  • Government organizations



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 673.92 Million (2018)
  CAGR   6.46% (2019-2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Information by Cancer Type, Treatment Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson Services, Inc. (US) and Hospira, Inc. (US)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising prevalence of anal cancer
  • The growing number of sexually transmitted diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Anal cancer market valuation was USD673.92 million

    Anal cancer market CAGR would be 6.46% during the forecast period.

    Anal cancer market top players are Celgene Corporation (US), Amgen Inc. (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Sanofi (France), Johnson & Johnson Services, Inc. (US,) GlaxoSmithKline plc (UK), and Hospira, Inc. (US)

    Anal cancer market in the Americas would be the largest.

    The Asia Pacific region would be the fastest-growing region for anal cancer market.

    Table of Contents

    1. REPORT PROLOGUE

    2. MARKET INTRODUCTION

    2.1. Definition

    2.2. Scope of the Study

    2.2.1. Research Objective

    2.2.2. Assumptions

    2.2.3. Limitations

    3. RESEARCH METHODOLOGY

    3.1. Overview

    3.2. Primary Research

    3.3. Secondary Research

    3.4. Market Size Estimation

    4. MARKET DYNAMICS

    4.1. Overview

    4.2. Drivers

    4.3. Restraints

    4.4. Opportunities

    5. MARKET FACTOR ANALYSIS

    5.1. Porter’s Five Forces Analysis

    5.1.1. Bargaining Power of Suppliers

    5.1.2. Bargaining Power of Buyers

    5.1.3. Threat of New Entrants

    5.1.4. Threat of Substitutes

    5.1.5. Intensity of Rivalry

    5.2. Value Chain Analysis


    6. GLOBAL ANAL CANCER MARKET, BY CANCER TYPE

    6.1. Overview

    6.2. Carcinoma in Situ

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3. Squamous Cell Carcinoma

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4. Adenocarcinoma

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5. Basal Cell Carcinoma

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.6. Melanoma

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.7. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7. GLOBAL ANAL CANCER MARKET, BY TREATMENT TYPE

    7.1. Overview

    7.2. Chemotherapy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3. Surgery

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4. Radiation Therapy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.5. Immunotherapy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8. GLOBAL ANAL CANCER MARKET, BY END USER

    8.1. Overview

    8.2. Hospitals & Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3. Research and Academic Institutes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9. GLOBAL ANAL CANCER MARKET, BY REGION

    9.1. Overview

    9.2. Americas

    9.2.1. North America

    9.2.1.1. US

    9.2.1.2. Canada

    9.2.2. Latin America

    9.3. Europe

    9.3.1. Western Europe

    9.3.1.1. Germany

    9.3.1.2. France

    9.3.1.3. Italy

    9.3.1.4. Spain

    9.3.1.5. UK

    9.3.1.6. Rest of Western Europe

    9.3.2. Eastern Europe

    9.4. Asia-Pacific

    9.4.1. Japan

    9.4.2. China

    9.4.3. India

    9.4.4. Australia

    9.4.5. South Korea

    9.4.6. Rest of Asia-Pacific

    9.5. Middle East & Africa

    9.5.1. Middle East

    9.5.2. Africa

    10. COMPANY LANDSCAPE

    10.1. Overview

    10.2. Competitive Analysis

    10.3. Market Share Analysis

    10.4. Major Growth Strategy in the Global Anal Cancer Market

    10.5. Competitive Benchmarking

    10.6. Leading Players in Terms of Number of Developments in the Global Anal Cancer Market

    10.7. Key Developments and Growth Strategies

    10.7.1. Product Launch/Service Deployment

    10.7.2. Mergers and Acquisitions

    10.7.3. Joint Ventures

    10.8. Major Players Financial Matrix & Market Ratio

    10.8.1. Sales & Operating Income 2020

    10.8.2. Major Players R&D Expenditure 2020

    10.9. Major Players Capital Market Ratio

    11. COMPANY PROFILES

    11.1. Amgen Inc.

    11.1.1. Company Overview

    11.1.2. Product Overview

    11.1.3. Financial Overview

    11.1.4. Key Developments

    11.1.5. SWOT Analysis

    11.1.6. Key Strategies

    11.2. Bristol-Myers Squibb Company

    11.2.1. Company Overview

    11.2.2. Product Overview

    11.2.3. Financial Overview

    11.2.4. Key Developments

    11.2.5. SWOT Analysis

    11.2.6. Key Strategies

    11.3. Celgene Corporation

    11.3.1. Company Overview

    11.3.2. Product Overview

    11.3.3. Financial Overview

    11.3.4. Key Developments

    11.3.5. SWOT Analysis

    11.3.6. Key Strategies

    11.4. Eli Lilly and Company

    11.4.1. Company Overview

    11.4.2. Product Overview

    11.4.3. Financial Overview

    11.4.4. Key Developments

    11.4.5. SWOT Analysis

    11.4.6. Key Strategies

    11.5. F. Hoffmann-La Roche Ltd

    11.5.1. Company Overview

    11.5.2. Product Overview

    11.5.3. Financial Overview

    11.5.4. Key Developments

    11.5.5. SWOT Analysis

    11.5.6. Key Strategies

    11.6. Merck & Co., Inc.

    11.6.1. Company Overview

    11.6.2. Product Overview

    11.6.3. Financial Overview

    11.6.4. Key Developments

    11.6.5. SWOT Analysis

    11.6.6. Key Strategies

    11.7. Novartis AG

    11.7.1. Company Overview

    11.7.2. Product Overview

    11.7.3. Financial Overview

    11.7.4. Key Developments

    11.7.5. SWOT Analysis

    11.7.6. Key Strategies

    11.8. Pfizer Inc.

    11.8.1. Company Overview

    11.8.2. Product Overview

    11.8.3. Financial Overview

    11.8.4. Key Developments

    11.8.5. SWOT Analysis

    11.8.6. Key Strategies

    11.9. GlaxoSmithKline plc

    11.9.1. Company Overview

    11.9.2. Product Overview

    11.9.3. Financial Overview

    11.9.4. Key Developments

    11.9.5. SWOT Analysis

    11.9.6. Key Strategies

    11.10. Sanofi

    11.10.1. Company Overview

    11.10.2. Product Overview

    11.10.3. Financial Overview

    11.10.4. Key Developments

    11.10.5. SWOT Analysis

    11.10.6. Key Strategies

    11.11. Johnson & Johnson Services, Inc.

    11.11.1. Company Overview

    11.11.2. Product Overview

    11.11.3. Financial Overview

    11.11.4. Key Developments

    11.11.5. SWOT Analysis

    11.11.6. Key Strategies

    11.12. Hospira, Inc.

    11.12.1. Company Overview

    11.12.2. Product Overview

    11.12.3. Financial Overview

    11.12.4. Key Developments

    11.12.5. SWOT Analysis

    11.12.6. Key Strategies

    11.13. Others

    12. APPENDIX

    12.1. References

    12.2. Related Reports


    LIST OF TABLES

    TABLE 1 GLOBAL ANAL CANCER MARKET SYNOPSIS, 2020-2027

    TABLE 2 GLOBAL ANAL CANCER MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 6 GLOBAL ANAL CANCER MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 7 NORTH AMERICA: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 8 NORTH AMERICA: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 9 NORTH AMERICA: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 10 US: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 11 US: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 12 US: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 13 CANADA: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 14 CANADA: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 15 CANADA: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 16 LATIN AMERICA: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 17 LATIN AMERICA: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 18 LATIN AMERICA: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 19 EUROPE: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 20 EUROPE: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 21 EUROPE: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 22 WESTERN EUROPE: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 23 WESTERN EUROPE: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 24 WESTERN EUROPE: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 25 EASTERN EUROPE: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 26 EASTERN EUROPE: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 27 EASTERN EUROPE: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 28 ASIA-PACIFIC: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 29 ASIA-PACIFIC: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 30 ASIA-PACIFIC: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 31 MIDDLE EAST & AFRICA: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

    TABLE 32 MIDDLE EAST & AFRICA: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 33 MIDDLE EAST & AFRICA: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)


    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET STRUCTURE OF THE GLOBAL ANAL CANCER MARKET

    FIGURE 3 MARKET DYNAMICS OF THE GLOBAL ANAL CANCER MARKET

    FIGURE 4 GLOBAL ANAL CANCER MARKET SHARE, BY CANCER TYPE, 2020 (%)

    FIGURE 5 GLOBAL ANAL CANCER MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

    FIGURE 6 GLOBAL ANAL CANCER MARKET SHARE, BY END USER, 2020 (%)

    FIGURE 7 GLOBAL ANAL CANCER MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 7 AMERICAS: ANAL CANCER MARKET SHARE BY REGION, 2020 (%)

    FIGURE 8 NORTH AMERICA: ANAL CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 9 EUROPE: ANAL CANCER MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 10 WESTERN EUROPE: ANAL CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 11 ASIA-PACIFIC: ANAL CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 12 MIDDLE EAST & AFRICA: ANAL CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 13 GLOBAL ANAL CANCER MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 14 AMGEN INC..: KEY FINANCIALS

    FIGURE 15 AMGEN INC.: SEGMENTAL REVENUE

    FIGURE 16 AMGEN INC.: REGIONAL REVENUE

    FIGURE 17 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

    FIGURE 18 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

    FIGURE 19 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

    FIGURE 20 CELGENE CORPORATION: KEY FINANCIALS

    FIGURE 21 CELGENE CORPORATION: SEGMENTAL REVENUE

    FIGURE 22 CELGENE CORPORATION: REGIONAL REVENUE

    FIGURE 23 ELI LILLY AND COMPANY: KEY FINANCIALS

    FIGURE 24 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

    FIGURE 25 ELI LILLY AND COMPANY: REGIONAL REVENUE

    FIGURE 26 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

    FIGURE 27 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

    FIGURE 28 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

    FIGURE 29 MERCK & CO., INC.: KEY FINANCIALS

    FIGURE 30 MERCK & CO., INC.: SEGMENTAL REVENUE

    FIGURE 31 MERCK & CO., INC.: REGIONAL REVENUE

    FIGURE 32 NOVARTIS AG: KEY FINANCIALS

    FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE

    FIGURE 34 NOVARTIS AG: REGIONAL REVENUE

    FIGURE 35 PFIZER INC.: KEY FINANCIALS

    FIGURE 36 PFIZER INC.: SEGMENTAL REVENUE

    FIGURE 37 PFIZER INC.: REGIONAL REVENUE

    FIGURE 38 GLAXOSMITHKLINE PLC: KEY FINANCIALS

    FIGURE 39 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

    FIGURE 40 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

    FIGURE 41 SANOFI: KEY FINANCIALS

    FIGURE 42 SANOFI: SEGMENTAL REVENUE

    FIGURE 43 SANOFI: REGIONAL REVENUE

    FIGURE 44 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

    FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

    FIGURE 46 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

    FIGURE 47 HOSPIRA, INC.: KEY FINANCIALS

    FIGURE 48 HOSPIRA, INC.: SEGMENTAL REVENUE

    FIGURE 49 HOSPIRA, INC.: REGIONAL REVENUE